Aura Biosciences (NASDAQ:AURA) Receives Buy Rating from HC Wainwright

Aura Biosciences (NASDAQ:AURA - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They presently have a $22.00 target price on the stock. HC Wainwright's price target points to a potential upside of 247.00% from the stock's previous close. HC Wainwright also issued estimates for Aura Biosciences' Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($1.87) EPS, FY2026 earnings at ($2.11) EPS and FY2027 earnings at ($1.64) EPS.

Separately, Lifesci Capital raised Aura Biosciences to a "strong-buy" rating in a research note on Friday, January 31st. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $23.00.

Aura Biosciences Trading Up 6.7 %

Shares of Aura Biosciences stock opened at $6.34 on Monday. The stock has a market cap of $316.69 million, a PE ratio of -3.66 and a beta of 0.30. Aura Biosciences has a 52 week low of $5.77 and a 52 week high of $12.38. The company's 50-day moving average price is $7.54 and its two-hundred day moving average price is $8.61.

Remove Ads

Aura Biosciences (NASDAQ:AURA - Get Free Report) last issued its earnings results on Monday, March 24th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.09). On average, equities analysts predict that Aura Biosciences will post -1.66 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Los Pinos Elisabet De sold 15,955 shares of the company's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total transaction of $122,374.85. Following the transaction, the insider now owns 304,692 shares of the company's stock, valued at $2,336,987.64. This represents a 4.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Over the last three months, insiders sold 23,045 shares of company stock valued at $177,242. Insiders own 5.40% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of AURA. BNP Paribas Financial Markets bought a new position in Aura Biosciences during the fourth quarter worth about $50,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Aura Biosciences during the fourth quarter worth $87,000. ProShare Advisors LLC acquired a new position in shares of Aura Biosciences in the 4th quarter valued at $127,000. Harvest Investment Services LLC acquired a new position in shares of Aura Biosciences in the 4th quarter valued at $133,000. Finally, AlphaQuest LLC bought a new stake in shares of Aura Biosciences in the 4th quarter valued at $136,000. Institutional investors own 96.75% of the company's stock.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.